PMV Pharmaceuticals Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PMV Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PMV Pharmaceuticals stock.
View analyst ratings for PMV Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given PMV Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but PMV Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

PMV Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,800,000 shares, an increase of 54.7% from the March 15th total of 1,810,000 shares. Based on an average daily volume of 155,600 shares, the days-to-cover ratio is presently 18.0 days. Currently, 8.8% of the company's shares are sold short.
View PMV Pharmaceuticals' Short Interest.

PMV Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, June 2nd 2021.
View our earnings forecast for PMV Pharmaceuticals.

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) posted its quarterly earnings results on Wednesday, March, 3rd. The company reported $3.53 earnings per share for the quarter, beating analysts' consensus estimates of ($1.27) by $4.80.
View PMV Pharmaceuticals' earnings history.

4 Wall Street analysts have issued 12 month price objectives for PMV Pharmaceuticals' stock. Their forecasts range from $34.00 to $42.00. On average, they anticipate PMV Pharmaceuticals' stock price to reach $38.00 in the next twelve months. This suggests a possible upside of 17.4% from the stock's current price.
View analysts' price targets for PMV Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to PMV Pharmaceuticals include Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT), Perrigo (PRGO), Allakos (ALLK), Blueprint Medicines (BPMC), Schrödinger (SDGR), Galapagos (GLPG), Biohaven Pharmaceutical (BHVN), Sage Therapeutics (SAGE), Hutchison China MediTech (HCM), Emergent BioSolutions (EBS), I-Mab (IMAB), Arena Pharmaceuticals (ARNA), Hypera (HYPMY) and Agios Pharmaceuticals (AGIO).
View all of PMVP's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other PMV Pharmaceuticals investors own include Vical (VICL), Arista Networks (ANET), Apollo Medical (AMEH), Advanced Micro Devices (AMD), Ambarella (AMBA), Alexion Pharmaceuticals (ALXN), Akoustis Technologies (AKTS), Agios Pharmaceuticals (AGIO), Admiral Group (ADM) and Adobe (ADBE).

(PMVP) raised $126 million in an initial public offering on Friday, September 25th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, BofA Securities, Cowen and Evercore ISI acted as the underwriters for the IPO.

PMV Pharmaceuticals trades on the NASDAQ under the ticker symbol "PMVP."

PMV Pharmaceuticals' lock-up period expired on Wednesday, March 24th. PMV Pharmaceuticals had issued 11,765,000 shares in its initial public offering on September 25th. The total size of the offering was $211,770,000 based on an initial share price of $18.00. Since the end of PMV Pharmaceuticals' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

PMV Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Interwest Venture Management Co. (12.21%). Company insiders that own PMV Pharmaceuticals stock include Leila Alland, Ra Capital Management, LP and Thilo Schroeder.
View institutional ownership trends for PMV Pharmaceuticals.

PMVP stock was sold by a variety of institutional investors in the last quarter, including Interwest Venture Management Co.. Company insiders that have sold PMV Pharmaceuticals company stock in the last year include Leila Alland, and Thilo Schroeder.
View insider buying and selling activity for PMV Pharmaceuticals or view top insider-selling stocks.

Shares of PMVP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PMVP stock can currently be purchased for approximately $32.37.

PMV Pharmaceuticals has a market capitalization of $1.45 billion.

PMV Pharmaceuticals employs 44 workers across the globe.

The official website for PMV Pharmaceuticals is www.pmvpharma.com.

The company can be reached via phone at 609 642 6670 or via email at [email protected]